In his weekly clinical update, Dr. Griffin highlights global circulation of Mpox virus, reviews the most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, and discusses the clinical outcome of hospitalized children under 5 years infected with SARS-CoV-2, the perinatal and neonatal outcomes including adverse effects of SARS-CoV-2 infection and virus transmission in Italy between early 2020 and 2022, the guidelines to improve home ventilation, the safety and efficacy of the oral anti-viral molnupiravir and the use of convalescent plasma as a long term treatment as well as treatment specifically for the immune compromised, the ineffectiveness of antibiotics for treating COVID-19, the association of olfactory dysfunction and the administration of corticosteroids and the safety of the RSV vaccines licensed last year.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Articles and graphs cited in TWIV CU 1076
• Global mpox circulation (WHO)
• Mpox in the Americas and Europe (CIDRAP)
• Respiratory disease surveillance (CDC)
• RSV surveillance (CDC)
• RSV national trend (CDC)
• Influenza/flu surveillance (CDC)
• Influenza/flu map (CDC)
• COVID-19 hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• Vaccine-Eligible Children Under-5 Years (PIDJ)
• Pre-school cohort vaccination rate (CIDRAP)
• Perinatal transmission and neonatal outcomes (IJID)
• Adverse maternal and neonatal effect (dgalerts)
• Ventilation home improvements (CDC)
• Quarantine/isolation guidelines (CDC)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma remmendation for immunocompromised (IDSociety)
• Corticosteroids in SARS-CoV-2
• Anticoagulation guidelines (hematology.org)
• Corticosteroids induced olfactory dysfunction (PLoS One)
• Convalescent Plasma Therapy: Long Term Implications (OFID)
• Preventing RSV infection by vaccination (MMWR)
• Antivirals and chronic kidney disease (CID) Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet Infectious Diseases)
• Contribute to our MicrobeTV fundraiser at PWB
• Letters read on TWiV 1076
• Dr. Griffin's COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]